Coherus Biosimilar Used ‘Scientific Justification’ To Skip Switch Study, Still Get Interchangeability With Lucentis

 
• By Sue Sutter
  
Lucentis Biosimilar Drug review profile
Cimerli was not subject to a 'switching' study prior to earning an interchangeability nod. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews